Company news

Xenon Pharmaceuticals Inc. news in 2026

Xenon Pharmaceuticals Inc.'s news releases, calls and decks from 2026, newest first.

View company

Xenon to Present at Upcoming Investor Conferences

November 3, 2026

Xenon to Report Q3 2026 Financial Results on November 9, 2026

November 2, 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 30, 2026

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

October 29, 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 21, 2026

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

September 17, 2026

Xenon to Present at Wells Fargo Healthcare Conference

September 3, 2026

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

August 26, 2026

Xenon Reports Q2 2026 Financial Results and Provides Business Update

August 6, 2026

Xenon to Report Q2 2026 Financial Results on August 6, 2026

July 30, 2026

Xenon Reports Q1 2026 Financial Results and Provides Business Update

May 7, 2026

Xenon to Report Q1 2026 Financial Results on May 7, 2026

April 30, 2026

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

April 19, 2026

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

April 6, 2026

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

March 12, 2026

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

March 9, 2026

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

March 8, 2026

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

March 7, 2026

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 16, 2026

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

January 12, 2026

Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Calls in 2026

Decks in 2026